Performance of the aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with hybrid capture 2 and cytology

Journal of Clinical Microbiology

Volumn 49, Issue 3, 2011, Pages 1071-1076

  Clad, Andreas ^a   Reuschenbach, Miriam ^b   Weinschenk, Johanna ^a   Grote, Ruth ^a   Rahmsdorf, Janina ^a   Freudenberg, Nikolaus ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA; VIRUS RNA;

ARTICLE; CANCER GRADING; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID ANALYSIS; PAPANICOLAOU TEST; PATIENT REFERRAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGNAL AMPLIFICATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

DNA, VIRAL; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

EID: 79952350930     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01674-10     Document Type: Article

References (30)

1. Agency for Health Care Policy and Research (AHCPR). 1999. Evaluation of cervical cytology: summary, evidence report/technology assessment, no. 5. Agency for Health Care Policy and Research, Rockville, MD. http://www .ahrq.gov/clinic/epcsums/cervsumm.htm. Accessed 8 October 2009.
2. Briolat, J., et al. 2007. HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN. Int. J. Cancer 121:2198-2204. (Pubitemid 47585598)
3. Castle, P. E., et al. 2007. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical pre-cancer and cancer. Clin. Cancer Res. 13(9):2599-2605.
4. Castle, P. E., et al. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11:1394-1399.
5. Cricca, M., et al. 2007. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol. Oncol. 106:549-557.
6. Cuschieri, K. S., M. J. Whitley, and H. A. Cubie. 2004. Human papillomavirus type specific DNA and RNA persistence: implications for cervical disease progression and monitoring. J. Med. Virol. 73:65-70.
7. Cuzick, J., et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101. (Pubitemid 44116919)
8. Czeglédy, J., et al. 1995. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? Int. J. Cancer 64:211-215.
9. Dalstein, V., et al. 2003. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer 106:396-403. (Pubitemid 36870403)
10. de Boer, M. A., et al. 2007. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin. Cancer Res. 13:132-138.
11. Digene Corp. 2007. Digene Hybrid Capture 2 high-risk HPV DNA test package insert. Digene Corp., Gaithersburg, MD.
12. Dockter, J., et al. 2009. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 45:S55-S61.
13. Gen-Probe Incorporated 2008. Gen-Probe APTIMA HPV Assay package insert. Gen-Probe Incorporated, San Diego, CA.
14. Getman, D., et al. 2009. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets. J. Clin. Virol. 45:S49-S54.
15. Gnanamony, M., et al. 2009. Human papillomavirus types 16 and 18 mRNA levels and not DNA levels may be associated with advancing stages of cervical cancer. Int. J. Gynecol. Cancer 19:1415-1420.
16. Koliopoulos, G., et al. 2007. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol. Oncol. 104:232-246.
17. Kotaniemi-Talonen, L., et al. 2008. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int. J. Cancer 123:2902-2906.
18. Monsonego, J., et al. 2010. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int. J. Cancer doi:10.1002/ijc.25726.
19. Muñoz, N., et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
20. National Cancer Institute. 2009. Human papillomaviruses and cancer: questions and answers. National Cancer Institute, Bethesda, MD. http://www .cancer.gov/cancertopics/factsheet/risk/HPV. Accessed 6 October 2009.
21. National Cancer Institute. 2009. Surveillance epidemiology and end results. Cancer: cervix uteri. http://seer.cancer.gov/statfacts/html/cervix. html. National Cancer Institute, Bethesda, MD. Accessed 8 October 2009.
22. Naucler, P., et al. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597.
23. Ronco, G., et al. 2006. Human papillomavirus testing and liquid-based cytology. J. Natl. Cancer Inst. 98(11):765-774.
24. Sotlar, K., et al. 2004. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol. 74:107-116.
25. Sun, C., et al. 2001. The significance of human papillomavirus viral load in prediction of histologic severity of and size of squamous intraepithelial lesions of uterine cervix. Gynecol. Oncol. 83:95-99.
26. Sun, C., et al. 2002. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int. J. Gynaecol. Obstet. 76:41-47.
27. Szarewski, A., et al. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
28. Wang-Johanning, F., D. W. Lu, Y. Wang, M. R. Johnson, and G. L. Johanning. 2002. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicaolaou tests using real-time polymerase chain reaction analysis. Cancer 94:2199-2210.
29. Wright, T. C., Jr., et al. 2007. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197:346-355.
30. Yoshida, T., et al. 2008. Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions. Int. J. Gynecol. Cancer 18:121-127.